Page last updated: 2024-12-11

3,7,11,15-tetramethyl-2-hexadecen-1-ol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,7,11,15-tetramethyl-2-hexadecen-1-ol: a fragrance ingredient; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5366244
CHEMBL ID390773
MeSH IDM0547066

Synonyms (24)

Synonym
LS-14831
(2e)-3,7,11,15-tetramethyl-2-hexadecen-1-ol
3,7,11,15-tetramethyl-2-hexadecen-1-ol
phytol, >=97%, fg
4305EBEF-F02F-4CB0-985E-89469C273922
CHEMBL390773
ai3-36488
(2e)-3,7,11,15-tetramethylhexadec-2-en-1-ol
AKOS008965402
S5121
253686-88-3
BOTWFXYSPFMFNR-HMMYKYKNSA-N
W-108070
2-hexadecen-1-ol, 3,7,11,15-tetramethyl
EN300-16645
F14923
AS-47652
AMY21944
CCG-267435
phytol 3,7,11,15-tetramethyl-2-hexadecen-1-ol
CS-0161167
3,7,11,15-tetramethyl-2-hexadecen-1-ol (mixture of isomers)
EN300-7399953
Z56347285
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1443719Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Cytotoxic dammarane-type triterpenoids from the leaves of Viburnum sambucinum.
AID1849967Substrate activity at 6xHis-tagged Streptococcus mutans UdpK expressed in Escherichia coli BL-21(DE3) assessed as measuring ADP level in presence of ATP/NADH by PK/LDH coupled assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Undecaprenol kinase: Function, mechanism and substrate specificity of a potential antibiotic target.
AID453949Antitubercular activity against Mycobacterium tuberculosis H37Rv by BACTEC460 radiometric susceptibility assay2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Antitubercular potential of some semisynthetic analogues of phytol.
AID1443717Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Cytotoxic dammarane-type triterpenoids from the leaves of Viburnum sambucinum.
AID1443716Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Cytotoxic dammarane-type triterpenoids from the leaves of Viburnum sambucinum.
AID713895Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 272942012European journal of medicinal chemistry, Mar, Volume: 49Recent advances in antitubercular natural products.
AID1443718Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay2017Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8
Cytotoxic dammarane-type triterpenoids from the leaves of Viburnum sambucinum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.39 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]